Back
REX American Resources Vs. Alnylam Pharmaceuticals Industry Stock Comparison
Sell
38
REX
REX American Resources
Last Price:
$39.61
Seasonality Move:
7.56%
Sell
41
ALNY
Alnylam Pharmaceuticals
Last Price:
$272.34
Seasonality Move:
7.6%
Sell
38
REX American Resources (REX)
is a Sell
Is REX American Resources a Buy, Sell or Hold?
-
The current REX American Resources [REX] share price is $38.61. The Score for REX is 38, which is 24% below its historic median score of 50, and infers higher risk than normal.
-
REX is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
-
This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
Sell
41
Alnylam Pharmaceuticals (ALNY)
is a Sell
Is Alnylam Pharmaceuticals a Buy, Sell or Hold?
-
The current Alnylam Pharmaceuticals [ALNY] share price is $269.21. The Score for ALNY is 41, which is 18% below its historic median score of 50, and infers higher risk than normal.
-
ALNY is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
-
This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
REX Stock Price Chart
What is REX American Resources's stock price today?
-
The REX American Resources share price today is $38.61Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and REX is experiencing slight selling pressure.
ALNY Stock Price Chart
What is Alnylam Pharmaceuticals's stock price today?
-
The Alnylam Pharmaceuticals share price today is $269.21Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and ALNY is experiencing selling pressure, which indicates risk of future bearish movement.
REX Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.88 | Sell |
| Relative Strength Index (14 RSI): | 54.6 | Buy |
| Chaikin Money Flow: | -81047 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (35.84 - 40.22) | Buy |
| Bollinger Bands (100): | (38.69 - 44.91) | Sell |
ALNY Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 5.33 | Buy |
| Relative Strength Index (14 RSI): | 56.44 | Buy |
| Chaikin Money Flow: | -958699 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (238.07 - 265.67) | Buy |
| Bollinger Bands (100): | (240.5 - 271.04) | Buy |
REX Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 36.91 | Buy |
| 20-day SMA: | 37.08 | Buy |
| 50-day SMA: | 39.99 | Sell |
| 200-day SMA: | 43.69 | Sell |
| 8-day EMA: | 37.13 | Buy |
| 20-day EMA: | 37.64 | Buy |
| 50-day EMA: | 39.38 | Sell |
| 200-day EMA: | 42.78 | Sell |
ALNY Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 266.08 | Buy |
| 20-day SMA: | 252.48 | Buy |
| 50-day SMA: | 259.02 | Buy |
| 200-day SMA: | 252.75 | Buy |
| 8-day EMA: | 268.02 | Buy |
| 20-day EMA: | 259.47 | Buy |
| 50-day EMA: | 256.9 | Buy |
| 200-day EMA: | 244.06 | Buy |
REX American Resources Earnings Growth & REX Earnings Dates
-
Analysts estimate an earnings increase this quarter of $0.19 per share, a decrease next quarter of $0.24 per share, an increase this year of $0.01 per share, and a decrease next year of $1.48 per share.
Alnylam Pharmaceuticals Earnings Growth & ALNY Earnings Dates
-
Analysts estimate an earnings increase this quarter of $0.91 per share, an increase next quarter of $0.05 per share, an increase this year of $1.08 per share, and an increase next year of $2.75 per share.
REX American Resources Technical Analysis
| Mar 13 | Mar 14 | Mar 17 | Mar 18 | Mar 19 | Mar 20 | Mar 21 | Mar 24 | Mar 25 | Mar 26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar | ||||||||||
| 13 | 14 | 17 | 18 | 19 | 20 | 21 | 24 | 25 | 26 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Alnylam Pharmaceuticals Technical Analysis
| Mar 13 | Mar 14 | Mar 17 | Mar 18 | Mar 19 | Mar 20 | Mar 21 | Mar 24 | Mar 25 | Mar 26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar | ||||||||||
| 13 | 14 | 17 | 18 | 19 | 20 | 21 | 24 | 25 | 26 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||